Genetic Immunity to Present at 2008 BIO International Convention

MCLEAN, Va. and BUDAPEST, Hungary, June 12 /PRNewswire/ -- Genetic
Immunity, a US/Hungarian clinical-stage Company focused on the development of
its patented nanomedicines for targeted immune amplification, announced today
that the Company will be presenting at the 2008 Bio International Convention
to be held June 17-20, 2008 at the San Diego Convention Center in San Diego,
CA. The Company's President and Chief Executive Officer, Dr. Julianna
Lisziewicz, is scheduled to present at the following times:
-- Wednesday, May 18 at 2:00 p.m. (PT): Dr. Lisziewicz will present an
overview of Genetic Immunity's nanomedicine technology platform and
clinical programs on as part of the infectious disease tract in room
5B.

-- Thursday, June 19th at 2:00 p.m. (PT): Dr. Lisziewicz will represent
Genetic Immunity in an international case study, "Biotechnology in
Hungary: Mission Possible," in room 26 AB.

For more information on this event please visit: http://www.bio2008.org.
While at the conference Genetic Immunity will discuss three partnering
opportunities. The first is focused on DermaVir Patch, which is the Company's
lead nanomedicine candidate for the treatment for HIV/AIDS. This topically
delivered nanomedicine is designed to amplify HIV-specific memory T cell
responses in order to kill HIV-infected cells specifically while leaving the
healthy cells intact.
The second opportunity is DermaPrep, which is a novel and proprietary
medical device that supports the topical delivery of macromolecules to lymph
nodes. DermaPrep is designed to mimic the body's response and has demonstrated
proof of concept with through development of the DermaVir Patch.
The third partnering option is the Company's patented NanoComp
nanoformulation technology that includes disease-specific, plasmid DNA-encoded
antigens. It is designed to improve the immunigenicity of antigens and induce
effective immune responses. NanoComp has also demonstrated proof of concept
with the DermaVir Patch, which includes HIV-specific plasmid DNA encoded
antigens.
About Genetic Immunity(R)
Genetic Immunity is a US/Hungarian clinical stage biopharmaceutical
company establishing leadership in Nanomedicines for targeted immune
amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly
specific medical intervention at the molecular scale for curing diseases or
repairing damaged tissues. The Company aims to discover, develop and
commercialize topically administered nanomedicines that can create new markets
for treating infectious diseases, cancer and allergies. These indications
represent a significant unmet medical need and the potential for alternative
treatment approaches. The DermaVir Patch, Genetic Immunity's lead nanomedicine
candidate, is in Phase II clinical development and could be the first
nanomedicine immune therapy for HIV-infected individuals. The DermaVir Patch
has demonstrated excellent safety, immunogenicity and antiviral efficacy in
preclinical studies. Phase I/II trials to date have confirmed safety and
tolerability and indicate the induction of long-lasting HIV-specific memory T
cells.
About the Nanomedicine Technology Platform
Genetic Immunity's nanomedicine immune amplification platform technology
is comprised of two principal components: NanoComp and DermaPrep. NanoComp is
a patented nanoformulation technology that includes disease-specific plasmid
DNA encoded antigens. DermaPrep is the topical administration device that
delivers NanoComp into a patient's lymph node dendritic cells to induce T cell
mediated immune responses that can treat a broad spectrum of diseases. These
two components together make up the DermaVir Patch. The plasmid DNA within
DermaVir Patch's NanoComp nanoparticles is specific to HIV and topically
delivered via DermaPrep to amplify the immune system to kill only HIV-infected
cells.
Contacts:
The Ruth Group
Investors
Sara Ephraim
+1-646-536-7002
sephraim@theruthgroup.com

Media
Janine McCargo
+1-646-536-7033
jmccargo@theruthgroup.com

www.geneticimmunity.com

SOURCE Genetic Immunity

Investors, Sara Ephraim, +1-646-536-7002, sephraim@theruthgroup.com, or Media,
Janine McCargo, +1-646-536-7033, jmccargo@theruthgroup.com, both of The Ruth
Group for Genetic Immunity